NO913665L - Immunoglobulin a1-proteaser fremgangsmaate for genteknologisk fremstilling av disse for immunisering mot sykdommer som foraarsakes av iga1-proteaseproduserende bakterier - Google Patents

Immunoglobulin a1-proteaser fremgangsmaate for genteknologisk fremstilling av disse for immunisering mot sykdommer som foraarsakes av iga1-proteaseproduserende bakterier

Info

Publication number
NO913665L
NO913665L NO91913665A NO913665A NO913665L NO 913665 L NO913665 L NO 913665L NO 91913665 A NO91913665 A NO 91913665A NO 913665 A NO913665 A NO 913665A NO 913665 L NO913665 L NO 913665L
Authority
NO
Norway
Prior art keywords
protease
iga1
influenzae
iga1 protease
iga
Prior art date
Application number
NO91913665A
Other languages
English (en)
Other versions
NO304745B1 (no
NO913665D0 (no
Inventor
Mogens Kilian
Knud Poulsen
Original Assignee
Mogens Kilian
Knud Poulsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogens Kilian, Knud Poulsen filed Critical Mogens Kilian
Publication of NO913665D0 publication Critical patent/NO913665D0/no
Publication of NO913665L publication Critical patent/NO913665L/no
Publication of NO304745B1 publication Critical patent/NO304745B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO913665A 1989-03-17 1991-09-17 Fremgangsmaate for fremstilling av immunglobulin A1-protease (IgA1-protease) eller immunogene fragmen ter derav NO304745B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK130889A DK130889A (da) 1989-03-17 1989-03-17 Immunoglobulin a1-proteaser (iga1-proteaser), fremgangsmaade til genteknologisk fremstilling af saadanne enzymer samt vaccine indeholdende enzymerne og fragmenter deraf til immunisering mod bakteriel meningitis og andre sygdomme fremkaldt af iga1-protease-producerende bakterier
PCT/DK1990/000073 WO1990011367A1 (en) 1989-03-17 1990-03-16 IMMUNOGLOBULIN A1 PROTEASES (IgA1 PROTEASES), METHOD OF GENE-TECHNOLOGICALLY PRODUCING THIS TYPE OF ENZYME AND VACCINES CONTAINING THE ENZYMES AND FRAGMENTS THEREOF FOR IMMUNIZING AGAINST BACTERIAL MENINGITIS AND OTHER DISEASES CAUSED BY IgA1 PROTEASE-PRODUCING BACTERIA

Publications (3)

Publication Number Publication Date
NO913665D0 NO913665D0 (no) 1991-09-17
NO913665L true NO913665L (no) 1991-11-18
NO304745B1 NO304745B1 (no) 1999-02-08

Family

ID=8103403

Family Applications (1)

Application Number Title Priority Date Filing Date
NO913665A NO304745B1 (no) 1989-03-17 1991-09-17 Fremgangsmaate for fremstilling av immunglobulin A1-protease (IgA1-protease) eller immunogene fragmen ter derav

Country Status (10)

Country Link
EP (1) EP0463073B1 (no)
JP (1) JPH04503756A (no)
AT (1) ATE174385T1 (no)
AU (1) AU630443B2 (no)
CA (1) CA2049984A1 (no)
DE (1) DE69032821D1 (no)
DK (1) DK130889A (no)
FI (1) FI100723B (no)
NO (1) NO304745B1 (no)
WO (1) WO1990011367A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965424A (en) * 1991-01-11 1999-10-12 Boehringer Mannheim Gmbh Methods for making neisseria or hemophilus IgA protease and DNA encoding the proteases
DE4140699A1 (de) * 1991-01-11 1992-07-16 Boehringer Mannheim Gmbh Rekombinante iga-protease
GB9201013D0 (en) * 1992-01-17 1992-03-11 Animal Health Inst Vaccines
US6245337B1 (en) 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
US6676948B2 (en) 1994-08-25 2004-01-13 Washington University Haemophilus adherence and penetration proteins
WO1996009395A2 (de) * 1994-09-21 1996-03-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Arzneimittel zur prophylaxe und behandlung von und diagnostika zur erkennung von autoimmunkrankheiten und viralen erkrankungen
US6559359B1 (en) * 1996-09-09 2003-05-06 Loyola University Of Chicago Plant retroviral polynucleotides and methods for use thereof
DK0895537T3 (da) * 1997-01-21 2005-03-29 Max Planck Gesellschaft IGA1 proteasefragment som bærerpeptid
DE19741955A1 (de) * 1997-09-23 1999-04-01 Max Planck Gesellschaft Mittel gegen bakterielle Meningitis
JP5438886B2 (ja) * 2003-03-07 2014-03-12 タフツ メディカル センター インコーポレイテッド ＩｇＡ１沈着症の治療
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
US8440191B2 (en) 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
US8841109B2 (en) 2009-04-20 2014-09-23 The University Of Kansas IGA1 protease polypeptide agents and uses thereof
RU2407792C1 (ru) * 2009-10-05 2010-12-27 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН СПОСОБ ПОЛУЧЕНИЯ IgAl-ПРОТЕАЗЫ ИЗ КУЛЬТУРЫ NEISSERIA MENINGITIDIS СЕРОГРУППЫ А И ИММУНОГЕННЫЙ ПРЕПАРАТ НА ЕЕ ОСНОВЕ
RU2426126C1 (ru) * 2010-05-28 2011-08-10 Федеральное государственное учреждение науки "Казанский научно-исследовательский институт эпидемиологии и микробиологии" Роспотребнадзора СПОСОБ ОПРЕДЕЛЕНИЯ IgA-ПРОТЕИНАЗНОЙ АКТИВНОСТИ
GB201120634D0 (en) * 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases

Also Published As

Publication number Publication date
EP0463073B1 (en) 1998-12-09
AU630443B2 (en) 1992-10-29
NO304745B1 (no) 1999-02-08
NO913665D0 (no) 1991-09-17
FI100723B (fi) 1998-02-13
AU5344790A (en) 1990-10-22
CA2049984A1 (en) 1990-09-18
DE69032821D1 (de) 1999-01-21
ATE174385T1 (de) 1998-12-15
JPH04503756A (ja) 1992-07-09
DK130889A (da) 1990-09-18
FI914356A0 (fi) 1991-09-17
EP0463073A1 (en) 1992-01-02
DK130889D0 (da) 1989-03-17
WO1990011367A1 (en) 1990-10-04

Similar Documents

Publication Publication Date Title
NO913665L (no) Immunoglobulin a1-proteaser fremgangsmaate for genteknologisk fremstilling av disse for immunisering mot sykdommer som foraarsakes av iga1-proteaseproduserende bakterier
Sugai et al. Purification and molecular characterization of glycylglycine endopeptidase produced by Staphylococcus capitis EPK1
RU95117238A (ru) Нуклеиновая кислота, рекомбинантная плазмида, рекомбинантный вектор, белок, синтетический пептид, химерная молекула, иммуногенная композиция, антисыворотка или антитела
Potempa et al. The multiple forms of trypsin-like activity present in various strains of Porphyromonas gingivalis are due to the presence of either Arg-gingipain or Lys-gingipain
CA2356836A1 (en) Novel streptococcus antigens
Yamamoto et al. Evidence that a non-O1 Vibrio cholerae produces enterotoxin that is similar but not identical to cholera enterotoxin
US8529911B2 (en) Small Streptococcus pyogenes antigens and their use
FI102539B1 (fi) Nitriilihydrataasiaktiivisuutta omaavaa polypeptidiä koodaava DNA-fragmentti, geenin sisältävä transformantti ja menetelmä amidien tuottamiseksi transformanttia käyttäen
Collins et al. Group G streptococcal M protein exhibits structural features analogous to those of class IM protein of group A streptococci
HU0004115D0 (no)
CA2224127A1 (en) Flagellin gene, flac of campylobacter
Wintermeyer et al. Characterization of legiolysin (lly), responsible for haemolytic activity, colour production and fluorescence of Legionella pneumophila
Pinkney et al. Different forms of streptolysin O produced by Streptococcus pyogenes and by Escherichia coli expressing recombinant toxin: cleavage by streptococcal cysteine protease
US5352588A (en) Streptococcal immunoglobulin a binding protein encoded by emmL2.2
DK128490D0 (da) Renset gensekvens, som koder for protein ia, ib eller begge fra neisseria gonorrhoeae, rekombinantvektorer og organismer indeholdende sekvenser, dens fremstilling og anvendelse, neisseria-stamme og dennes paavisning
KR19990007306A (ko) 클로스트리디움 페르프링겐스 백신
Gerlach et al. Characterization of two genes encoding antigenically distinct type-1 fimbriae of Klebsiella pneumoniae
JPH0195791A (ja) 新規なポリペプチド、その製法、そのためのベクター及びそれを含有する医薬
von Eichel-Streiber Molecular biology of the Clostridium difficile toxins
Gotschlich et al. Gonococcal protein III. Purification and chemical characterization of the protein, and the DNA sequence of the structural gene
WO1988009668A1 (en) Treatment and diagnosis of footrot using the basic protease of b. nodosus
EP0623170A1 (en) Vaccines based on streptokinase
Chestukhina et al. Amino acid sequences from the N-terminal domain of Bacillus thuringiensis, subspecies alesti, δ-endotoxin: Hypervariable regions of Bacillus thuringiensis δ-endotoxms
EP0411715A2 (en) Modified proteases, process for their preparation and their use in foodstuffs
Yamamoto et al. Biological roles of a novel class of cysteine proteinases from Porphyromonas gingivalis in periodontal disease progression